Trial Profile
Predictive efficacy of serum soluble PD-L1 on patients with metastatic renal cell carcinoma treated with Nivolumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 01 May 2023 Results evaluating sPD-L1 in mRCC patients treated with nivolumab and investigating the association between sPD-L1 and treatment response, presented at the 118th Annual Meeting of the American Urological Association
- 28 Jan 2023 Results assessing soluble PD-L1 levels in patients with mRCC treated with nivolumab and investigated its association with treatment response, published in the Anticancer Research.
- 07 Oct 2020 Planned End Date changed from 30 Apr 2024 to 30 Apr 2023.